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Level of Evidence: 4 
ABSTRACT 
Background: This study is a pilot study evaluating the feasibility of sampling nose-blood 
during an emergency using a commercially available rapid test device. It also compares the 
accuracy of rapid nasal blood test results to the results of standard laboratory methods using 
venous blood sampling. 
Methodology: Nose-blood was collected in patients suffering from active epistaxis. In an 
emergency setting, haemoglobin levels and the international normalized ratio (INR) were 
assessed using a rapid point-of-care test device. These results were compared to standard 
laboratory analyses from venous blood taken at the same time from the same patient. Twenty 
patients consented to and participated in these assessments. 
Results: Linear regression comparing venous and nasal samples revealed strong correlations 
between the two methods for both haemoglobin and INR measurement. A Bland-Altman 
analysis showed the mean difference to be 2.3 g/l when comparing haemoglobin 
measurements made using the rapid point-of-care device to haemoglobin measurements made 
using conventional lab assessment. The corresponding mean difference for INR 
measurements was 0.14. 
Conclusions: The results of this pilot study support the use of point-of-care test devices using 
nasal blood sampling and provide preliminary data demonstrating that a rapid testing method 
can be reliable, practicable and time-efficient. In our opinion rapid hematologic screening for 
nasal and capillary blood should be available in emergency wards which treat epistaxis. 
 
 
 
 
 
 
 
 
 
INTRODUCTION 
The treatment of epistaxis (nosebleed) is routine for otolaryngologists, emergency specialists 
and general practitioners. More than half of all adults have had or will experience an episode 
of nosebleed[1]. This is often harmless and self-limiting, and may be managed by the patient. 
Nevertheless, severe cases require medical attention and may potentially lead to relevant and 
measurable blood loss. Anaemia due to epistaxis can usually be attributed either to a single 
episode being particularly severe or due to recurring bleeding[2]. 
In anticoagulated patients, management algorithms incorporating lab haematology findings 
play a decisive role. Of the lab values that haematology tests deliver, Hb (haemoglobin) often 
serves physicians as a threshold indicator for the initiation or adaptation of therapy. For 
example, blood transfusions are given if Hb is low, Hb levels help determine whether or not 
vitamin K substitution is necessary in a severely anticoagulated patient, and the removal of 
nasal packs in high risk patients with anaemic Hb levels should be prolonged for another 24 
hours[3].  
Though routine laboratory screening is considered useful or even recommended for the 
paediatric population[4, 5], similar lab screening for anaemia or coagulopathies is not 
recommended in otherwise healthy epistaxis patients[6]. The decision to evaluate Hb and INR 
during an emergency is instead based upon the patient’s history, the resources available in the 
particular emergency setting, and it takes into account clinic or medical system specific 
economic considerations. Indeed, the gold standard for hematologic testing, namely venous 
puncture and blood sampling involving laboratory analysis, is time consuming and acutely 
ties up medical staff. Furthermore, it is painful for the patient and generates financial 
expenses. It is possible direct sampling could avoid many of these inconveniences, at least in 
cases of epistaxis. Direct, rapid-test sampling of the nasal blood could effectively mitigate the 
inherent pathologic mischief of the nosebleed by providing clinicians the opportunity to 
exploit the fact that patient is already bleeding to diagnostic and health-economic advantage. 
Commercially available, rapid test devices for capillary blood analyses exist. By making use 
of one, it is possible the workload for doctors and medical/hospital staff, caused by high 
volumes of epistaxis patients and it’s time-consuming routine therapeutic and diagnostic 
procedures, could be reduced, that time and expense could be saved, and pain on the part of 
the patient could be avoided. Furthermore, the clinical and economical threshold for acquiring 
valuable hematologic information could conceivably be lowered. The dual aims of this pilot 
study were a) to evaluate the clinical feasibility of sampling relatively impure nose-blood 
using two commercially available rapid test devices, and b) to compare the reliability of the 
rapid-test devices to standard venous blood sampling involving lab analysis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
MATERIALS AND METHODS 
This investigation was designed as a prospective pilot study at the University Hospital of 
Zurich. Between March 2015 and June 2015 we collected blood samples from 20 epistaxis 
patients. Patients suffering from active nosebleed of a sufficient volume were included in the 
study during their treatment at the university hospital’s ENT emergency ward. After briefly 
orienting a patient regarding the study and securing definitive oral consent, we immediately 
initiated treatment. After primary treatment, we repeated the informed consent process for the 
sake of verification, this time without the stress of the nosebleed and its treatment, and 
obtained formal written consent. We collected data regarding the patient’s demographic 
details, any history of antithrombotic medication, the localization of the bleed site (i.e. the 
specific nasal location), the INR and Hb values using nasal blood, and the INR and Hb values 
as collected via standard venous-blood harvesting methods (analysed in the hospital’s 
diagnostic lab). 
To avoid dilution of the nasal blood, we did not apply local anaesthesia or vasoconstrictive 
agents before collecting nasal blood samples. Two to three drops of nose-blood were caught 
directly on the INR test strip of the “Roche CoaguChek XS Plus®” rapid-testing device. We 
transferred some of the blood from this relatively ‘big’ drop to a Hb test strip using a 
microcuvette (HemoCue Hb 201+®). The standard venous blood sample was taken a few 
minutes after treatment of the bleed and sent to the university hospital’s on-site laboratory for 
evaluation. The outputs of the two rapid devices, namely Hb in grams per litre and INR in per 
cent, were compared to the results of the standard lab testing procedure. 
The statistical analyses and charts were conducted using the Statistical Package for the Social 
Sciences software package (SPSS), Version 22.0.0.1 (IBM Corp., Armonk, NY, USA). The  
data were analysed for agreement using a method described by Bland and Altman[7] in which 
graphs are used to compare the differences of individual measurements to a mean difference.  
The study was conducted in accordance with the latest version of the Helsinki declarations 
and with the permission of canton Zurich’s ethics committee (KEK-ZH-Nr.: 2014-0679, 
ClinicalTrials.gov-Identifier: NCT02370381). It was investigator initiated and financed by 
University Hospital Zurich’s ENT department. The HemoCue Hb 201+® device was provided 
on loan and cuvettes were offered free of charge by an independent local distributor. The 
Roche CoaguChek XS Plus® device was already part of our emergency equipment. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RESULTS 
Twenty patients provided written informed consent following initial oral consent and 
emergency treatment and were included in this study. None of the patients approached to 
participate withdrew the initial oral consent they had given prior to receiving treatment. 
The cohort included 14 (70%) male and 6 (30%) female patients. The mean age of the patients 
at the time of epistaxis treatment was 64.4 years (SD 18.9 [24.6 – 89.2 years]). An anterior 
nasal bleed location was the most commonly observed location, seen in 75% (15) of the 
population. Sixty-five percent of the patients reported prior intake of haemostasis impairing 
medication. This included 8 (40%) patients who had taken only acetylsalicylic acid (ASA), 1 
(5%) patient who took ASA in conjunction with other medications, and 3 (15%) patients who 
had had only a vitamin K antagonist (VKA). One patient was known to suffer from hereditary 
haemorrhagic telangiectasia. 
The mean Hb level measured in venous blood was 140 g/l [range 95-167 g/l]. The average 
nasal blood Hb level was 138 g/l [range 88-179 g/l]. Linear regression comparing Hb values 
derived using conventional venous puncture as the dependent variable and nose-blood Hb as 
an independent variable demonstrated a positive correlation (r=0.85; p<0.01). Figure 1. 
Bland-Altman analysis showed that the average observed difference between measurements 
taken using the two test-types was 2.3 g/l with a 95% confidence interval (CI) - 20.8 g/l to 
25.4 g/l. On average, this is slightly less than a 2% difference separating the measures 
delivered by rapid nasal blood testing and venous blood lab testing. Figure 2. This small 
difference would seem clinically irrelevant, and a one-sample t-test demonstrated that this 
average difference is indeed statistically insignificant (reference value 0). This suggests that 
the measurement discrepancies between the two test modalities (on average around 2.3 g/l) 
are irrelevant. The lack of linear correlation between the difference of values and the mean 
difference confirmed that no proportional bias was present (p=0.1). There were two outliers 
outside the 95% CI. In one case Hb was overestimated in the nasal sample by 23 g/l. In 
another patient it was underestimated by 40 g/l. These outlying values would not, however, 
have altered the course of treatment or a decision to provide a blood transfusion. 
The mean INR value measured in our patient’s venous blood was 1.2 [range 1-3.3]. For nasal 
blood the comparable mean value was 1.3 [range 0.8-2.2]. Figure 3. Again, linear regression 
using venous puncture INR as the dependent variable and nose-blood INR as an independent 
variable demonstrated a significant correlation (r=0.86, p<0.01). The mean difference 
between measurements was 0.14 [95% CI -0.5;0.8] was demonstrably not significant (one 
sample T-test p=0.08). However, there was a positive correlation between the mean difference 
and the mean value of the two measurements. This suggests that higher values have a higher 
risk of bias. For these sample sets two outliers were observed (95% CI): In one case nasal 
INR was 1.3 lower than the INR of the corresponding venous sample. In the second case the 
nasal sample measurement was 0.6 greater than the venous measurement. In the latter case, 
the patient was ultimately determined to have a normal INR, and we noted that this was the 
same patient for which a low-lying nasal blood Hb outlier value had been observed (an 
apparent undervaluation of the true Hb value). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DISCUSSION 
Our study shows the feasibility, cost effectiveness and accuracy of sampling nasal blood for 
the analysis of haemoglobin and INR values using point of care devices in epistaxis.  
Hb and INR testing are amongst the most commonly performed blood tests in an epistaxis 
emergency setting. Time-intensive analyses usually have a naturally high threshold, impeding 
their initiation and often avoided in the midst of a clinical emergency. Indeed, when treating 
epistaxis at the emergency ward, it is fairly likely, that after the usually short treatment the 
patient has to wait another hour just for the lab results to arrive. Especially for cases with a 
high probability for anaemia, an Hb level has to be acquired before the patient can be 
discharged.  
The additional expenditure of cost and time has led to the general consensus that routine 
assessment of blood values in an epistaxis emergency is not considered to be a staple of 
general practice[4]. In an earlier investigation conducted at the Zurich University Hospital, 
high-risk transfusion cohorts were identified and characterized without the contemplation of 
blood values. The acronym THREAT (Trauma, Hematologic disorder, and REAr origin of 
bleeding) helps to remember and identify the factors associated with an increased risk of 
receiving blood transfusion[8]. Recent studies and growing recognition in the field of 
otolaryngology suggest that increased access to INR and Hb levels in epistaxis patients could 
be beneficial and worth recommending in specific patient populations.  
A work examining a population of paediatric epistaxis patients revealed a 22% rate of 
anaemia and a 7.8% rate of bleeding disorders[5]. This study group has gone so far as to 
propose routine screening of all paediatric epistaxis patients for anaemia and coagulopathies. 
Screening this population would prevent to leave many at-risk children untreated, and prone 
to the potentially harmful long-term consequences, at the costs of a painful blood sample. 
More than a third of patients on vitamin K antagonists are outside of the INR target range in 
the setting of epistaxis[9, 10]. Thus, it would seem epistaxis is an apparent indicator of a 
possible overexposure to antithrombotic medication, and testing to confirm this suspicion 
shouldn’t be forgone. The consequences of not doing so, and the resultant overtreatment or 
undertreatment with blood thinners has been shown to lead to higher mortality[11].  
Rapid test devices strain healthcare budgets much less than expenses generated via traditional 
laboratory analyses. Based on Swiss market prices, a single rapid Hb micro-cuvette costs 1 
Swiss Franc (CHF). This equates to approximately 1 US Dollar (USD) at the current 
exchange rate (Jan. 2016). In comparison, the current cost of lab testing at our institution is 
nine times higher, 9 CHF (approx. 9 USD). Further increasing the costs, our in-house 
laboratory measures Hb using a hemogram, which unavoidably also assesses hematologic 
parameters beyond what is needed. A similar cost-imbalance exists for the INR testing, with 
rapid testing costing 3.5 CHF vs 6 CHF for conventional lab testing. The calculations 
presented here are admittedly basic. Many peripheral and non-material costs are not being 
fully considered, both for conventional venous blood testing, as well as for rapid nasal blood 
testing. These costs include but are not limited to the material for venipuncture sampling, 
transport to the lab, personell costs, and other intangibles. The acquisition of a rapid test 
device amounts to less than 1000 CHF. Maintenance and quality controls can easily be 
conducted without any professional knowledge by the user. 
Obvious limitations apply to it, as patients without active bleeding are not amenable to nasal 
blood testing. Often these patients transition to an active nasal drip after intranasal 
manipulation during the treatment. Pragmatically, if nasal blood isn’t available during 
treatment, the same devices could of course be used for capillary tests. This raises the issue, of 
course, that these rapid testing devices were not designed with nasal blood testing explicitly in 
mind. A reliable validation of these devices’ applicability for use with nasal blood requires a 
larger scale study. 
It’s important to note, however, that the reasons nasal blood Hb and INR measurements 
occasionally deviate from venous sampling values remain unclear. Dilution prior to sampling 
could be the cause for high INR and low Hb levels. Beyond this, it is possible that the 
enzymatic activity of nasal secretions might also bias measurements. The proteins present in 
these secretions could potentially lead to haemolysis and degradation.  
Although our study, a pilot study, has a relatively small sample size (n = 20), the nasal Hb 
levels we observed were strikingly in-line with values delivered by conventional means. The 
accuracy of our Hb results using rapid test devices for nasal blood is well comparable to the 
accuracy when matching capillary with venipuncture testing[12, 13]. Also, our INR testing 
results for nasal blood were quite comparable to those reported by other studies comparing the 
merits of capillary blood testing to conventional venous testing[14]. Indeed the limits of 
agreement for INR were even narrower in our results. A positive proportional bias with 
greater differences for INR values at a higher range was also observed. The differences 
between nasal and conventional blood testing were ultimately clinically irrelevant and even 
the outliers mentioned wouldn’t have had a negative effect on treatment or the indication for 
transfusion. Indeed, the observed deviations from rapidly sampled nasal blood resulted in Hb 
underestimation and INR overestimation. Thus, it is actually less likely that a rapid test device 
would fail to report a critically low Hb or a critically high INR level, keeping in mind that 
these types of errors are less dangerous for the patient than the other way around. 
 
 
 
 
 
 
 
 
 
CONCLUSION 
Our pilot study demonstrates the feasibility, reliability and the utility of conducting Hb and 
INR testing noninvasively using nose-blood in epistaxis patients and a point-of-care rapid test 
method.  
Furthermore, it highlights the possible advantages that rapid testing may have over 
conventional venipuncture. Nasal blood testing could represent an easy, fast, painless and cost 
saving type of Hb and INR measurement. In emergencies, rapid course of action is paramount 
in order to make the right decisions and to improve the patient’s outcome. 
In our opinion rapid hematologic screening for nasal and capillary blood should be available 
in emergency wards which treat epistaxis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ADDENDUM 
Rafael R. Stadler obtained the consent of the local ethic committee, performed the patient 
enrolment, performed the data collection, analysed the raw data and prepared the manuscript. 
Michael B. Soyka has planned, supervised and designed the study. Acting as the principal 
investigator he helped with the analysis, prepared and reviewed the manuscript. 
Nicolas Newcomb - from the Institute of Evolutionary Medicine, University of Zurich UZH, 
Zurich Switzerland  - edited the manuscript. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE LEGENDS 
Figure 1: Linear Model comparing the level of haemoglobin. The level of haemoglobin on the 
x-axis was measured from a venous puncture by the laboratory in g/l and the level of Hb on 
the y-axis was measured from nose-blood by the rapid test device in g/l. 
 
Figure 2: Bland-Altman plot showing the differences between the HbLab (laboratory) and 
HbNose (rapid test device) in g/l plotted against the mean value of both measurements in the 
same patient. The horizontal lines mark the 95% confidence limit. 
 
Figure 3: The differences between the INRLab (laboratory) and INRNose (rapid test device) 
in % are shown at the mean level of both measurements (Bland-Altman plot) of each patient. 
The horizontal lines mark the 95% confidence limit. 
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